Skip to main content

Aggrastat Side Effects

Generic name: tirofiban

Medically reviewed by Last updated on Sep 18, 2022.

Note: This document contains side effect information about tirofiban. Some dosage forms listed on this page may not apply to the brand name Aggrastat.

Applies to tirofiban: intravenous solution.

Serious side effects of Aggrastat

Along with its needed effects, tirofiban (the active ingredient contained in Aggrastat) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking tirofiban:

More common

  • Abdominal or stomach pain or swelling
  • arm, back, or jaw pain
  • black, tarry stools
  • blood in the eyes
  • blood in the urine
  • bruising or purple areas on the skin
  • chest pain or discomfort
  • chest tightness or heaviness
  • coughing up blood
  • decreased alertness
  • fast or irregular heartbeat
  • headache
  • joint pain or swelling
  • nausea
  • nosebleeds

Less common

  • Bleeding gums
  • lightheadedness or fainting
  • pinpoint red spots on the skin
  • severe, unusual tiredness or weakness
  • slow heartbeat
  • swelling of the hands, ankles, feet, or lower legs

Incidence not known

  • Chills or fever
  • cough
  • difficulty swallowing
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • skin rash, hives, or itching
  • trouble breathing

Other side effects of Aggrastat

Some side effects of tirofiban may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Pain in the legs or hips

Less common

For Healthcare Professionals

Applies to tirofiban: intravenous powder for injection, intravenous solution.


Bleeding is the most common adverse reaction. Clinical trial adverse reactions were reported in patients taking this drug in addition to heparin.[Ref]


Very common (10% or more): Thrombolysis in myocardial infarction (TIMI) minor bleeding (up to 10.5%)

Common (1% to 10%): TIMI major bleeding, transfusions, platelets decreased to less than 90,000 cells/mm3

Uncommon (0.1% to 1%): Platelets decreased to less than 50,000 cells/mm3

Postmarketing reports: Platelets decreased to less than 10,000 cells/mm3, fatal bleeding[Ref]

Nervous system

Common (1% to 10%): Vasovagal reaction, dizziness, headache

Postmarketing reports: Intracranial bleeding[Ref]


Common (1% to 10%): Bradycardia, coronary artery dissection

Postmarketing reports: Hemopericardium[Ref]


Common (1% to 10%): Nausea

Postmarketing reports: Retroperitoneal bleeding[Ref]


Common (1% to 10%): Edema/swelling

Postmarketing reports: Spinal epidural hematoma[Ref]


Common (1% to 10%): Sweating[Ref]


Common (1% to 10%): Pelvic pain[Ref]


Common (1% to 10%): Leg pain[Ref]


Postmarketing reports: Severe allergic reactions, anaphylactic reactions[Ref]


Postmarketing reports: Pulmonary hemorrhage[Ref]


1. "Product Information. Aggrastat (tirofiban)." Merck & Co., Inc (2001):

2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

3. Cerner Multum, Inc. "Australian Product Information." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.